Company Information
CIN
Status
Date of Incorporation
28 February 1991
State / ROC
Ahmedabad / ROC Ahmedabad
Last Balance Sheet
31 March 2023
Last Annual Meeting
25 August 2023
Paid Up Capital
800,100,000
Authorised Capital
1,206,500,000
Directors
Manvantkumar Shankerlal Rami
Director/Designated Partner
almost 2 years ago
almost 2 years ago
Parul Nikunj Shah
Director/Designated Partner
almost 2 years ago
almost 2 years ago
Ajit Singh
Director/Designated Partner
almost 2 years ago
almost 2 years ago
Niraj Vinodkumar Jain
Manager/Secretary
about 2 years ago
about 2 years ago
Girdhar Prem Balwani
Director/Designated Partner
about 2 years ago
about 2 years ago
Akhilesh Jain
Manager/Secretary
over 2 years ago
over 2 years ago
Sundaresan Anandanarayanan
Company Secretary
over 3 years ago
over 3 years ago
Amitava Mukherjee
Director
about 6 years ago
about 6 years ago
Pratima Ram
Director/Designated Partner
over 6 years ago
over 6 years ago
Pradip Navin Khandwalla
Director
over 6 years ago
over 6 years ago
Manoj Kumar Srivastava
Manager/Secretary
about 7 years ago
about 7 years ago
Abhijat Chandrakant Sheth
Director/Designated Partner
about 7 years ago
about 7 years ago
Jaswinder Matharu
Director/Designated Partner
about 8 years ago
about 8 years ago
Ramesh Ratilal Choksi
Director/Designated Partner
over 11 years ago
over 11 years ago
Monika Garware
Director
almost 30 years ago
almost 30 years ago
Rajiv Indravadan Modi
Director/Designated Partner
almost 35 years ago
almost 35 years ago
Past Directors
Daya Nand Khurana
Director
over 6 years ago
over 6 years ago
Prashant Arunkumar Mehta
Company Secretary
about 8 years ago
about 8 years ago
Atul Malhotra
Director
almost 12 years ago
almost 12 years ago
Govind Shanker Pandey
Whole Time Director
about 12 years ago
about 12 years ago
Narendra Jamnadas Jhaveri
Additional Director
over 12 years ago
over 12 years ago
Chinubhai Ramanlal Shah
Director
over 24 years ago
over 24 years ago
Shilaben Indravadan Modi
Director
almost 30 years ago
almost 30 years ago
Indravadan Ambalal Modi
Managing Director
over 30 years ago
over 30 years ago
Patents
Present invention relates to the method of treating cancer. According to present invention, a pharmaceutical composition made from "Mycobacterium w'(Mw) is found to be useful in the management of caner. We have now found that the same therapeutic agent is useful in management of cancer. The use of Mycobacterim w con...
The invention relates to process for the preparation of formulations comprising a microorganism Mycobacterium w for the treatment of tuberculosis.
Antihistamines are available in the from of free bases as well as salts i. e. hydrochloride, maleate, tannate ect.Frequently, it is necessary to utilise antihistamines in the from of tannate salt because such salts are generally quite stable and may be administered in such from without untoward side effects. Tannic ...
The present invention provides a oral pharmaceutical composition of an acid labile drugs characterized in a)core containing acid labile drug,b)sub coat,a separating layer,c)seal coat is a layer which separate the sub coat with enteric coat.The seal coat is consisting of water insoluble but water permeable material l...
THE PROCESS OF MANUFACTURING IMMUNOMODULATORS TO TREAT HIV DISEASE/INFECTION
Humman Immunodeficiency virus causes depletion of CD4 cells. The depletion of CD4 cells results in decrease in immunity of an infected individual. Due to decrease immunity various opportunistic infections occur. These infections are cause ...
Present invention relates to the process of manufacturing a pharmaceutical composition useful for management of cancer. According to present invention, a pharmaceutical composition made from 'Mycobacterium w' (Mw) is found to be useful in the management of cancer. We have now found that the same therapeutic agent is...
Human Immunodeficiency virus causes depletion of CD4 cells. The depletion of CD4 cells results in decrease in immunity of an infected individual. Due to decrease immunity various opportunistic infections occur. These infections are cause for morbidity and mortality in HIV infected individuals. The treatment of HIV t...
This invention relates to a method for prophylaxis or therapy for AIDS, or AIDS related complex (ARC) comprising administration of a formulation which is prepared using mycobacterium w or immunomodulator obtained from mycobacterium w alone or in combination and also with or without adjuvants to a subject who has bee...
The present invention relates to improving outcome of current therapies for Non Small cell Lung Cancer, particularly that of Squamous cell carcinoma of the lung.
The present invention relates to a process for the preparation of 6-fluoro-3,4-dihydro-2H-chromene-2-carbaldehyde which is useful as an intermediate in the synthesis of Nebivolol or its pharmaceutical acceptable salts.
The present invention relates to an improved process for preparation of Atorvastatin calcium in amorphous form. Tine invention also reates to an improved process for the preparation of amorphous atorvastatin calcium comprising: reaction of (βR,ỡR)-2-(4-fuorophenyl)-β-ỡ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenyI...
This invention discloses the process for lyophilisation of the treated cells which
comprises the use of a solution containing Trehalose along with amphipathic polymer Polyvinylpyrrolidone. Further the invention discloses the process treating cancer cells, freezing, lyophilizing and reconstituting. Immunomodulator t...
The present invention is to provide a controlled release pharmaceutical composition comprises of highly soluble drug and plant derived product like Hydrogenated oils as sole controlled release matrix forming excipient which reduces or eliminates the initial burst effect and control the release of highly soluble drug...
The present invention relates to novel hypoglycemic compounds of formula I and pharmaceutically acceptable salts thereof. The invention relates to novel amino acid derivatives of the formula I,
The present invention provides a process for the preparation of monoisoamyl meso-2, 3-dimercaptosuccinate (MiADMSA) with high purity wherein purification of monoisoamyl meso-2, 3-dimercaptosuccinate (MiADMSA) is carried out using a solvent mixture of hydrocarbon and ether.
The present invention relates to a novel process for the conversion of (2R)-6-fluoro-2-[(2S)-oxiran-2-yl]-3,4-dihydro-2H-chromene (formula lll-A) to (2R)-6-fluoro-2-[(2R)-oxiran-. 2-yl]-3,4-dihydro-2H-chromene (formula Ill-B). The compound of formula lil-A and formula lll-B are key intermediates for preparing Nebiv...
The present invention relates to a process for preparation of Fluticasone Propionate having structural Formula-1 with substantially free of ester impurity.
The present invention relates to process for preparation of novel compounds which are acting as inhibitors of dipeptidyl peptidase-IV enzyme and is depicted by the structural formula as given below.
(Compound of Formula VI) Which are useful in the treatment or prevention of diseases in which the dipeptidylpeptid...
AN IMPROVED ONE-POT PROCESS FOR THE PREPARATION OF
CHLORHEXIDINE
The invention relates to an improved one pot process for the preparation of Chlorhexidine by reaction of hexamethylene diamine with sodium dicynamide in alcohol, using hydrochloric acid and a base, followed by reacting 1,1'-hexane-1,6-diylbis(3-cya...
The present invention relates to a novel clear stable self-emulsifying liquid pharmaceutical composition of Curcumin or its pharmaceutically acceptable salts or derivatives devoid of pH buffer and/or molecular aggregator inhibitor(s) wherein the Curcumin is solubilized in liquid pharmaceutical composition to make a ...
The present invention relates to a process for the removal of. t-butyl group from t-butyl methyl 4-(2",3"-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate to provide-1,4-dihydro-2,6-dimethyl-4-(2,,3,-dichorophenyl)-5-methoxycarbonyl-3-pyridine-carboxyfic acid, which is further converted to to yiel...
The present invention relates to a process for the preparation of clevidipine intermediate-(Butanoyloxy) methyl (2Z)-2-(2,3-dichiorobenzylidene)-3-oxobutanoate and its conversion to clevidipine.
The invention relates to novel process for providing pure 6-Fluoro-3-ptperidin-4-yl-1,2-benzisoxazole hydrochloride and its conversion to substantially pure Paliperidone containing less than 0.1 % of dimer impurity having structural formula compound of formula-1A. OH Formula 1a [Dimer impurity]
...
The invention relates to an improved process for preparation of 3-(2-hydroxy ethyl)-9-hydroxy-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one or its acid addition salt and its conversion to palipendone or its acid addition salt.
The present invention relates to a novel and improved process for the preparation of n-[4-[2-(dimethylamino)ethoxy]benzyl]-3,4-dimethoxybenzamide- known as Itopride, via a novel intermediate N-(4-hydroxybenzyl)-3,4-dimethoxybenzamide.
The present invention discloses a novel process to prepare a compound of formula IIA. By reacting a compound of formula-[D] wherein R1 is C1 to C6 alkyl, preferably R1 is methyl or ethyl, more preferably R1 is methyl; and R2 is C1 to C8 n-alkyl or branched alkyl, cycloalkyl, phenyl, benzyl or substituted phenyl grou...
The invention is to provide a process for the preparation of Carvedilol by reacting l-(9H-carbazol-4-yloxy)-3-chloropropan-2-ol or l-(9H-carbazol-4-yloxy)-3-bromopropan-2-ol with 2-(2-methoxyphenoxy)-ethylamine. Yet another object of the invention is to provide a process for the preparation of Carvedilol by reacting...
The invention provides new process for preparing Carvedilol by reaction of 4-(oxiran-2-yl-methoxy)-9H-carbazole and substituted silyl protected 2-(2-methoxy phenoxy)-ethylamine compound to give silyl protected Carvedilol intermediate. The silyl protected Carvedilol intermediate on desilylation gives Carvedilol. The ...
The invention relates to a novel adjuvant Mycobacterium w and or its constituents and adjuvant containing composition, which contains antigen (s) with pharmaceutical acceptable carrier and its uses. Mycobacterium w and or its constituents when administered with antigen (s) to mammal results in enhanced immunogenicit...
The present invention related to hypolipaemic pharmaceutical compositions comprising lipid lowering agents and BAR antagonist such as 3(3-hydroxy pregna-5,16-dien-20-one (Herein known as 16 DP), Guggulsterones. 16 DP is also given a compound number 80/574.
The invention relates to a process for the preparation of carvedilol (1-(9H-carbazol –4-yloxy)-3-[[2-(2-methoxyphenoxy) ethyl]amino]-2-propanol) of 99% purity and in yield >55%, in the reaction of 4-(oxyran-2-ylmethoxy)-9H-carbazole with 2-(2-Methoxyphenoxy)-ethylamine, which comprises carrying out said reaction in ...
The present invention relates to modulation of Mitogen-activated protein kinases (MAPK) using Mycobacterium w (Mw).
The present invention relates to a novel method for preparation of sertraline hydrochloride form II from sertralone on an industrial scale.
The present invention relates to preparation of N-(3-chloro-4-fluoro-phenyl)-7-methoxy- 6-(3-morphoIin-4-yIpropoxy) quinazofin-4-amine.
The present invention relates to a novel process for purification of Rabeprazole using 2-butanone.
A process for preparing Desloratadine in a mixture of Desloratadine polymorphs form 1 and form 2, in a predetermined ratio by maintaining the water content of solution of Desloratadine obtained by dissolving desloratadine in hydrocarbon solvent. The % of form1 and form 2 of Desloratadine is ascertained by using IR m...
The present invention relates to preparation of 2-substituted 1-cyclopropyl-2-(2-fluorophenyl)ethanone, which is used as an intermediate for the preparation of 5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridine-2-yl acetate. The present inventiob provides a novel / alternative pr...
The present invention relates to a pharmaceutical composition comprising rifampicin and piperine with optimal enhancement in bioavailability of rifampicin by piperine. The present invention further relates to process for preparing pharmaceutical composition comprising rifampicin and piperine.
The present invention relates to pharmaceutical compositions comprising rifampicin, piperine as a bioenhancer for rifampicin and isoniazid is in delayed release form, wherein the said pharmaceutical compositions have maintained bioavailability of rifampicin in presence of isoniazid. The present invention further rel...
Methscopolamine Tennate is prepared from methscopolamine salt and tannic acid salt in aqueous medium. Methscopolamine salt is Methscopolamine bromide or nitrate, preferably methscopolamine bromide, whereas tannic acid salt is an alkali metal salt of tannic acid, preferably potassium salt of tannic acid. The preparat...
Olmesartan medoxomil of high purity (99.3-99.7% by HPLC) is prepared using an improved process of its intermediate, namely-ethyl-4-(1-hydroxy-1-methylethyl) 2-propyl-1-[[2’-[2-(triphenylmethyl)-2H-tetrazol-5yl]biphenyl-4-yl]methyl]imidazole-5-carboxylate, comprising: Reacting ethyl-4-(1-hydroxy-1-methylethyl)-2-prop...
2-Butyl-3-[[2’-(1H-tetrazol-5-yl)[1,1’-biphenyl]-4-yl]methyl]-1, 3-diaza-spiro[4,4]non-1-en-4-one is prepared by reacting 1-(2’-cyanobiphenyl-4-yl)methyl)-2-n-butyl-4-spirocyclopentane-2-imidazolin-5-one with sodium azide and zinc halide, in organic solvent.
The invention relates to novel adjuvant that can stimulate the mammalian immune
system against a wide variety of antigen(s). The invention also provides novel adjuvants to potentiate effect of other adjuvants along with their compositions and a novel method of identifying compounds for use as adjuvant(s). Invention...
The present invention relates to solid oral dosage form for the treatment of non-insulin dependent type diabetes (diabetes of type II) using a combination of pharmaceutically acceptable salt of Metformin and Glibenclamide containing essentially and/or along with other excipients.
The novel stable novel pharmaceutical composition comprising of non-steroidal anti-inflammatory drug (NSAIDs), as injectables, which provides a clear and stable pharmaceutical composition without incorporation of any additives.
The present invention relates to commercially feasible process for the purification of benzyl nebivolol which involves separating RSSS/SRRR isomeric pair of benzyl " nebivolol from the mixture of RSSS/SSSR and RSRR/SRSS benzyl nebivolol isomers.
Nebivolol is useful in the treatment and prevention of coronary vascular disorders. The present invention provides a process for the preparation of 6-fluoro-3,4-dihydro-2H-1-benzopyran-2-carboxaldehyde from the mixture containing undesired isomers of Nebivolol using periodic acid or its salt.
The process described ...
A one pot process for the preparation of 4-propylthio-1,2-phenylenediamine (formula I) from 4-thiocyanato-2-nitroaniline (formula II), an intermediate in the preparation of albendazole which reduces number of steps, reaction time and, provides an easy workup procedure without the use of toxic reagents.
...
The invention relates to an improved process for the preparation of Paliperidone in high yield and purity. The purity of Paliperidone is -99.7 % by HPLC, wherein total impurity is less than about 0.3 % and each individual impurity is less than about 0.1 %. The invention also relates to provide the alcohol-water co-s...
A novel process is disclosed for the preparation of imidazo [1,2- α] pyridine-3-acetic acid compounds and derivatives thereof, and more particularly Zolpidem. The process to prepare Zolpidem involves a “One pot” process for the conversion of 2-(4-methylphenyl)-6-methylimidazo [1,2- α] pyridine –3-acetic acid. The no...
The present invention relates to a stable solid oral pharmaceutical multi-component composition comprising combination of blood pressure lowering drugs with lipid lowering agent/s and optionally a platelet aggregation inhibitor in a single dosage form. The blood pressure lowering agents are selected from (3-adrenerg...
The present invention is to provide a stable parenteral clear liquid pharmaceutical composition of the nebivolol or its pharmaceutically acceptable salts or derivatives, wherein nebivolol or its pharmaceutically acceptable salts or derivatives is in soluble form.
The invention relates to an improved process for amorphous atorvastatin calcium.
Pregabalin is useful for the treatment and prevention of seizure disorders, pain, and psychotic disorders. The present invention relates to an improved process for the preparation of Pregabalin involving the use of a mixture of two acids one of which is (S)-(+) mandelic acid and second is achiral organic acid or a m...
The present invention relates to an improved process for purification of pioglitazone
Using a mixture of solvents involving toluene and alcohol.
The present invention relates to an improved method for the preparation of Desloratadine with reduced levels of organic solvents. Further the invention also relates to a process for the preparation of Desloratadine containing reduced level of chloroform and hexane in Desloratadine to meet ICH specifications. The inv...
The invention relates to novel p38 MAPK inhibitor which involves Mycobacterium w and/or its constituents in pharmaceutically acceptable carriers and their uses. Mycobacterium w and/or its constituents when administered to mammal results in p38 inhibition. The inhibition is found to last more than 28 days. It is also...
A Novel device for Intradermal injection referred in figure 1-10 comprising bottom surface “A” and top surface “B”. It includes channel/tunnel (1) to guide needle syringe assembly in intradermal space, on surface “B”. Stoppering mechanism (2) to control penetration of the tip of the needle into intradermal space is...
Mycobacterium w or its components are found to have poly TLR antagonistic activity induced TLRs by varieties of TLR ligands. The induced TLR against which inhibitory effect is seen includes TLR 3, 4, 5, 6, 7, 8, 9. They also display antagonistic activities to effects of TLR ligands. They are also useful in managemen...
A process of preparation of (4-oxo-2-thioxo-1,3-thiazolidin-3-yl) acetic acid from a compound of formula [X] Where R=C1-8 alkyl, benzyl, cycloalkyl, C1-6 alkylene, phenyl, substituted phenyl etc. which is prepared by, a base catalyzed intermolecular cyclization of a compound of formula [IX] where R1 is C1-4 alkyl, ...
Present invention relates to the mehtod providing prophylaxis for tuberculosis in HIV positive individuals. According to present invention, vaccine made from 'Mycobacterium w' (Mw) is found to be useful in proiding prophylaxis against tuberculosis in HIV positive individuals.
The present invention relates to a novel method for preparing trityl losartan and losartan potassium form I.
The present invention relates to a method of preparing a stable pharmaceutical composition of raberprazole.The preparation may be used as an injectable dosage from in the treatment of severe gastric ulcers.
PROCESS FOR MANUFACTURING PHARMACEUTICAL COMPOSITION CONTAINING ANTIRETROVIRAL PROTEASE INHIBITOR WITH IMPROVED BIOAVAILABILITY
The present invention relates to a process for manufacturing pharmaceutical composition containing antiretroviral inhibitor with improved bioavailability.According to present invention i...
The present invention provides the stable oral pharmaceutical compositions having improved bioavailability comprising Tacrolimus or its pharmaceutically acceptable salts or its derivatives, alcohol, oil and low concentration of surfactant and process for the preparation of the same.
The present invention relates to a stable palatable oral liquid pharmaceutical composition comprising Ranitidine hydrochloride, ion exchange resin, co-solvent, pH modifier, viscosity modifier and other pharmaceutically acceptable excipients. The said oral liquid pharmaceutical composition is stable for at least 18 m...
The of preparing the topical anti-inflammatory and analgesic preparation comprising of a) Extraction of herbal ingredients in an appropriate sovent; b) Concentrating the extraction of step a; c) Filtration of the concentrated solution of step b; d) Addition of oil base to the filtrate of step c; e) Removal of solven...
The present invention relates to an improved process for the preparation of
substantially pure Telmisartan in polymorphic form A.
The present invention relates to the solid oral pharmaceuticals composition of lacidipine having desired dissolution rate and the process for preparation of the same without the use of surfactant(s) and/or disintegrant(s) and micronization.
THE PROCESS FOR MANUFACTURING OF CLEAR LIQUID PHARMACEUTICAL COMPOSITION OF AZITHROMYCIN
Azithromycin is a macrolide antibiotic used for treating infection. This is available also for treating severe infection by intravenous administration of the drug.
Currently it is not possible to manufacturing liquid preparati...
PHARMACEUTICAL COMPOSITION OF TAXOIDS
The present invention relates to the stable oral pharmaceutical composition with improved solubility and bioavailability; comprising of taxoid, solubilizer, stabilizing agent, surfactant(s), solvent(s), and oil wherein the concentration of taxoid is in the range of 0.1 to 10%.
...
The present invention relates to an improved process for the preparation of agomelatine starting from reaction of 7-methoxy-1-tetralone with organozinc compound.
The invention relates to an improved process for preparation of 3-{2-chloroethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one, an intermediate used in the synthesis of paliperidone and process for converting the same to Paliperidone.
The invention relates to the method of treating tuberculesis comprises use of a microorganism Mycobacterium w for the treatment of tuberculosis.
PHARMACEUTICAL COMPOSITION FOR MYDRIASIS AND PROCESS FOR PRODUCING SAME.
The present invention relates to pharmaceutical composition for mydriasis and process for producing same. The pharmaceutical composition as per present invention provides better mydriasis. The amount of mydtiasis produced is more and in...
The present invention relates to a process for the preparation of pranlukast substantially free of brominated impurities.
The present invention is directed to novel compounds of formula I and pharmaceutical^ acceptable salts, enantiomers thereof having inhibiting properties of dipeptidyl peptidase IV enzyme (DP-IV inhibitors): The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these ...
The present invention provides a novel process for the preparation of O-desmethyl venlafaxine
from venlafaxine or its salt. Venlafaxine or its salt is L7-demethylated to provide 0-
desmethylvenlafaxine in high yield and purity by reacting venlafaxine or its salt with trimethyl
silyl halide and metal sulfide at ...
The present invention provides an improved process for the synthesis of Nebivolol and its pharmaceutically acceptable salts, more particularly hydrochloride salt of formula
(I).
Formula I
Invention involves one pot synthesis of Nebivolol from epoxy monomer, which proceeds stereo specifically, in high yield, wi...
Cancer cells when treated with cisplatin, paclitaxel, gemcitabine, Mycobacterium w or combination there of shows altered protein profile. Thus altered protein profile has at least one protein commonly expressed or over expressed. The commonly expressed or over expressed protein induces immune response specific to ca...
The present invention relates to a process for the preparation of Bosentan (Formula 1) or pharmaceutically acceptable salts or hydrates thereof which results the product substantially free of impurities like ethylene glycol bis-sulfonamide dimer and 6-hydroxy sulfonamide. The process according to present invention i...
THE PROCESS FOR PREPARING A STABLE AND PALATABLE PHARMACEUTICAL COMPOSITION FAT SOLUBLE VITAMINS WITH VITAMIN C.
Fat soluble vitamins like vitamin E is used along with vitamin C for many therapeutic indications. Vitamin E also has an unpleasant taste. For this reason it is supplied in soft gelatin capsules. It is ...
The present invention relates to novel stable indole-3-carbinol derivatives of Formula-I and its pharmaceutical composition and biological activity. The present invention includes compositions and methods for the treatment and prevention of conditions associated with Inflammation.
Nateglinide is prepared by an improved process comprising reaction of trans-4- isopropyl cyclohexane carbonyl chloride with N,O-bis- trimethylsilyl protected D-phenyl alamine to give after aqueous workup, crude nateglinide which is converted to Nateglinide form-H using a mixture of cyclohexane/ethyl acetate. Trans -...
The invention relates to preparation of amorphous rabeprazole sodium from rabeprazole using sodium tertiary butoxide in tertiary butyl alcohol. The preparation further avoids the use of halogenated solvents, and freeze drying.
The present provides a preparation of (+/-) -5- [substituted phenyl methyl ] – 2,4- thiazolidinediones from 5–[ substituted benzylidene ]-2,4-thaizolidiones by catalytic hydrogenation using precious catalyst, using DMF or formic acid [ or aqueous formic acid] and perchloride acid.
The invention relates to an improved process
for the preparation of 4-[2-(methyl-2-pyridinylamino)
ethoxy]-benzaldehyde via 4-[2-(methyl-2-pyridinylami-
no).ethoxy]-benzonitrile.
The process of preparation of
4-[2-(methyl-2-pyridi-nylamino)ethoxy]-benzaldehyde comprises:
(a) Reacting 2[methyl(pyridine-2-...
The invention relates to the HMG-COA reductase inhibitor in particular to Atorvastatin Hemi-calcium. The present invention is directed to novel processes for preparing amorphous form of Atorvastatin hemi calcium and their intermediate in high purity.
The present invention relates to a continuous process for preparing Ethambutol dihydrochloride (Formula-1) by reacting d-2-amino-butan-1-ol (d2AB) and ethylene dichloride (EDC) in a different mole ratio more particularly lower mole ratio than conventional mole ratio being used at higher temperature and pressure usin...
The present invention relates to Sodium Hyaluronate Polymer of tailored molecular weights. In one embodiment, tailored molecular weight of hydrolysed Sodium hyaluronate polymer range from about 0.6-1.45 million Dalton. To obtained tailored molecular weights of Sodium hyaluronate firstly Bulk Sodium hyaluronate, is ...
The present invention relates to vaccine(s) comprising cancer cells expressing antigen(s), excipients, optionally adjuvant wherein the said antigen(s) is expressed on contacting the said cancer cell with p38 inducer, for use in treatment of Cancer. The vaccine composition induces specific immune response against hom...
The present invention relates to an improved process for the conversion of 8-nitro -2-cyano -4H -1-benzopyran-4-one to 8-nitro-2- (1H – tetrazol -5-yl)-4H – 1 – benzopyran-4-one using sodium azide with zinc halides, in water, 8-nitro-2- (1H- tetrazol -5-yl)-4H – 1 –benzopyran-4-one is further converted to 8-amino-2-...
The present invention relates to a novel process for the purification of prahlukast to
obtain pranlukast with total impurities < 0.2%, preferably < 0.1% and without pale yellow tinge.
The present invention provides an improved process for the preparation of 6-fluoro-2-(oxiran-2-yl)-3,4-dihydro-2H-chromene having structural Formula-1 in desired diastereomeric mixture devoid of impurities.
The present invention provides a stable pharmaceutical composition comprising (a) Metformin hydrochloride treated with alkalizing agent; b) a DPP-IV inhibitor; and (c) one or more pharmaceutically acceptable excipients and a process for the preparation thereof.
The present invention relates to an improved commercially scalable process for the preparation of 2-(6-Chloro-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl)-benzonitrile of formula (II), a key intermediate for the preparation of Alogliptin and pharmaceutically acceptable salts thereof in high yields and hig...
The object of present invention is to provide a stable aqueous parenteral composition exhibiting enhanced bio-availability comprising 300000 to 600000 IU of Vitamin D3, substantially free from alcohol and oil.
The present invention relates to novel intermediate(s), which are useful for the preparation of Rivastigmine compound of formula (I) and its pharmaceutically acceptable salts. The present invention further relates to the processes for the preparation of such novel intermediate(s) and preparation of Rivastigmine usin...
An improved process for the preparation of pure Labetalol hydrochloride of formula (I), substantially free from 3-Bromo Labetalol impurity or having 3-Bromo Labetalol impurity < 0.05% by HPLC.
The present invention provides a cost-effective industrial process for the preparation of Cariprazine compound of formula (I) or its pharmaceutically acceptable salts.
AN IMPROVED PROCESS FOR PREPARATION OF VORTIOXETINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
ABSTRACT
The present invention is to provide an improved process for preparation of Vortioxetine and its pharmaceutically acceptable salts via amide compound of formula (IV) and/or acid compound of formula (V).
...
AN IMPROVED PROCESS FOR PREPARATION OF VORTIOXETINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
ABSTRACT
The present invention is to provide an improved process for preparation of Vortioxetine compound of formula (I) and its pharmaceutically acceptable salts via ester compound of formula (IV) and/or acid compound ...
AN IMPROVED PROCESS FOR PREPARATION OF VORTIOXETINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
ABSTRACT
The present invention is to provide an improved process for preparation of Vortioxetine and its pharmaceutically acceptable salts via acid compound of formula (IV).
A NOVEL PROCESS FOR THE PREPARATION OF HIV INHIBITORS
ABSTRACT
The present invention relates to an improved process for the preparation of HIV inhibitor compounds of formula (I) and pharmaceutically acceptable salts thereof. The present invention further relates to a novel intermediate compound i.e. methyl 3-...
AN AQUEOUS PARENTERAL COMPOSITION OF VITAMIN D3
ABSTRACT
The present invention relates to a clear aqueous parenteral composition comprising 300000 to 600000 IU of Vitamin D3, surfactant is less than 5% w/v and more than 0.5% w/v, a solvent system, and pharmaceutically acceptable excipients; wherein the solvent i...
A CLEAR AQUEOUS PARENTERAL COMPOSITION OF VITAMIN D3
ABSTRACT
The present invention relates to an aqueous parenteral composition comprising Vitamin D3 and a solvent system, wherein the solvent system comprises more than 5% w/v of surfactant and optionally less than 5% w/v of transcutol or less than 5% w/v of gly...
Registered Trademarks
[Class : 5] Pharmaceutical And Medicinal Preparations
[Class : 5] Pharmaceuticals And Medicinal Preparations
[Class : 5] Pharmaceuticals And Medicinal Peparations
View +1104 more Brands for Cadila Pharmaceuticals Limited.
Charges
12 April 2019
Bank Of Baroda
75 Crore
24 December 2018
Canara Bank
75 Crore
09 April 2018
Union Bank Of India
75 Crore
29 June 2017
Hdfc Bank Limited
60 Crore
07 October 2016
Idfc Bank Limited
60 Crore
06 May 2016
Corporation Bank
60 Crore
25 March 2014
Export-import Bank Of India
35 Crore
10 February 2014
Bank Of Baroda
125 Crore
29 November 2013
Union Bank Of India
50 Crore
17 October 2012
Bank Of Baroda
50 Crore
31 January 2008
Hdfc Bank Limited
43 Lak
13 September 2005
Bank Of Baroda
450 Crore
21 June 2002
Bank Of Baroda
1,277 Crore
08 March 2001
Exprot- Import Bank Of India
10 Crore
08 January 2001
Export - Import Bank Of India
10 Crore
27 August 1999
Export - Import Bank Of India
10 Crore
18 November 1998
Bank Of Baroda
300 Crore
08 April 2009
Department Of Biotechnology
25 Lak
09 April 2012
Export-import Bank Of India
42 Crore
18 April 2011
Indian Overseas Bank
50 Crore
20 December 2011
Bank Of Baroda
65 Crore
21 December 2010
Bank Of Baroda
48 Crore
28 May 2001
Corporation Bank
50 Lak
28 December 2007
Canara Bank
10 Crore
29 November 2000
Corporation Bank
90 Lak
01 December 2000
Indian Bank
3 Crore
21 June 1999
Icici Limited
45 Crore
12 April 2002
Canara Bank
2 Crore
06 October 2003
Canara Bank
4 Crore
29 September 2000
Bank Of Baroda
6 Crore
23 October 2002
Bank Of Baroda
5 Crore
15 September 1997
Bank Of Baroda
1 Crore
28 March 2003
Bank Of Baroda
22 Crore
18 April 2003
Bank Of Baroda
3 Crore
22 March 2002
Bank Of Baroda
1 Crore
19 November 1998
Bank Of Baroda
78 Crore
21 January 2002
Union Bank Of India
31 Lak
23 June 2006
Syndicate Bank
24 Crore
11 July 2006
Syndicate Bank
15 Crore
23 June 2006
Syndicate Bank
10 Crore
23 June 2006
Syndicate Bank
25 Crore
23 July 2008
Allahabad Bank
9 Crore
28 April 2010
Export Import Bank Of India
30 Crore
26 May 2010
Central Bank Of India
40 Crore
11 December 2009
Central Bank Of India
25 Crore
31 July 2006
Corporation Bank
25 Crore
27 March 2009
Dena Bank
140 Crore
29 July 2006
Syndicate Bank
15 Crore
13 September 2005
Bank Of Baroda
68 Crore
29 March 2003
Canara Bank
30 Crore
11 October 2005
Exprot-import Bank Of India
20 Crore
27 September 2007
The Karnataka Bank Limited
3 Crore
26 March 2004
State Bank Of India
30 Crore
24 September 2001
The Karnataka Bank Ltd.
10 Crore
27 March 2001
Export - Import Bank Of India
20 Crore
28 March 2003
Allahbad Bank
22 Crore
20 March 2006
Bank Of Baroda
6 Crore
22 October 2003
Corporate Bank
15 Crore
16 May 2001
Union Bank Of India
0
29 March 2001
Union Bank Of India
0
19 September 2003
Export - Import Bank Of India
0
15 January 2002
Rabo India Finance Pvt. Ltd.
20 Crore
30 March 2000
Syndicate Bank
14 Crore
09 March 2000
Oriental Bank Of Commerce
1 Crore
28 February 2001
Oriental Bank Of Commerce
15 Crore
30 November 2000
Oriental Bank Of Commerc
7 Crore
07 January 2000
Industrial Developoment Bank Of India
15 Crore
28 November 2001
Andhra Bank
15 Crore
15 October 1999
Central Bank Of India
17 Crore
07 March 2000
Icici Limited
30 Crore
02 November 2000
Indian Overseas Bank
10 Lak
11 September 1999
Idbi Bank Limited
7 Crore
25 June 2021
Axis Bank Limited
37 Crore
29 April 2020
Bank Of Baroda
75 Crore
02 March 2020
Canara Bank
75 Crore
27 December 2019
Corporation Bank
75 Crore
29 September 2023
Canara Bank
0
27 June 2023
Hdfc Bank Limited
0
23 June 2023
Bank Of India
0
24 March 2023
Axis Bank Limited
0
17 March 2023
Others
0
10 February 2014
Bank Of Baroda
0
02 March 2020
Canara Bank
0
24 December 2018
Canara Bank
0
31 March 2022
Others
0
29 November 2013
Union Bank Of India
0
02 November 2021
Bank Of India
0
29 April 2020
Others
0
09 April 2018
Others
0
12 April 2019
Others
0
27 August 1999
Export - Import Bank Of India
0
07 October 2016
Others
0
31 July 2006
Corporation Bank
0
21 June 2002
Others
0
29 June 2017
Hdfc Bank Limited
0
24 September 2001
The Karnataka Bank Ltd.
0
01 December 2000
Indian Bank
0
08 January 2001
Export - Import Bank Of India
0
28 February 2001
Oriental Bank Of Commerce
0
15 January 2002
Rabo India Finance Pvt. Ltd.
0
22 March 2002
Bank Of Baroda
0
18 April 2003
Bank Of Baroda
0
19 September 2003
Export - Import Bank Of India
0
22 October 2003
Corporate Bank
0
29 November 2000
Corporation Bank
0
30 March 2000
Syndicate Bank
0
09 March 2000
Oriental Bank Of Commerce
0
07 March 2000
Icici Limited
0
21 June 1999
Icici Limited
0
19 November 1998
Bank Of Baroda
0
17 October 2012
Bank Of Baroda
0
09 April 2012
Export-import Bank Of India
0
20 December 2011
Bank Of Baroda
0
21 December 2010
Bank Of Baroda
0
11 October 2005
Exprot-import Bank Of India
0
11 December 2009
Central Bank Of India
0
23 July 2008
Allahabad Bank
0
25 June 2021
Axis Bank Limited
0
29 July 2006
Syndicate Bank
0
11 July 2006
Syndicate Bank
0
23 June 2006
Syndicate Bank
0
23 June 2006
Syndicate Bank
0
20 March 2006
Bank Of Baroda
0
06 May 2016
Others
0
28 April 2010
Export Import Bank Of India
0
23 June 2006
Syndicate Bank
0
27 December 2019
Others
0
27 September 2007
The Karnataka Bank Limited
0
28 December 2007
Canara Bank
0
31 January 2008
Hdfc Bank Limited
0
27 March 2009
Dena Bank
0
08 April 2009
Department Of Biotechnology
0
26 May 2010
Central Bank Of India
0
18 April 2011
Indian Overseas Bank
0
25 March 2014
Export-import Bank Of India
0
28 March 2003
Allahbad Bank
0
13 September 2005
Bank Of Baroda
0
15 September 1997
Bank Of Baroda
0
18 November 1998
Others
0
11 September 1999
Idbi Bank Limited
0
07 January 2000
Industrial Developoment Bank Of India
0
29 September 2000
Bank Of Baroda
0
30 November 2000
Oriental Bank Of Commerc
0
08 March 2001
Exprot- Import Bank Of India
0
27 March 2001
Export - Import Bank Of India
0
29 March 2001
Union Bank Of India
0
16 May 2001
Union Bank Of India
0
28 May 2001
Corporation Bank
0
28 November 2001
Andhra Bank
0
21 January 2002
Union Bank Of India
0
12 April 2002
Canara Bank
0
23 October 2002
Bank Of Baroda
0
28 March 2003
Bank Of Baroda
0
29 March 2003
Canara Bank
0
06 October 2003
Canara Bank
0
26 March 2004
State Bank Of India
0
13 September 2005
Others
0
15 October 1999
Central Bank Of India
0
02 November 2000
Indian Overseas Bank
0
29 September 2023
Canara Bank
0
27 June 2023
Hdfc Bank Limited
0
23 June 2023
Bank Of India
0
24 March 2023
Axis Bank Limited
0
17 March 2023
Others
0
10 February 2014
Bank Of Baroda
0
02 March 2020
Canara Bank
0
24 December 2018
Canara Bank
0
31 March 2022
Others
0
29 November 2013
Union Bank Of India
0
02 November 2021
Bank Of India
0
29 April 2020
Others
0
09 April 2018
Others
0
12 April 2019
Others
0
27 August 1999
Export - Import Bank Of India
0
07 October 2016
Others
0
31 July 2006
Corporation Bank
0
21 June 2002
Others
0
29 June 2017
Hdfc Bank Limited
0
24 September 2001
The Karnataka Bank Ltd.
0
01 December 2000
Indian Bank
0
08 January 2001
Export - Import Bank Of India
0
28 February 2001
Oriental Bank Of Commerce
0
15 January 2002
Rabo India Finance Pvt. Ltd.
0
22 March 2002
Bank Of Baroda
0
18 April 2003
Bank Of Baroda
0
19 September 2003
Export - Import Bank Of India
0
22 October 2003
Corporate Bank
0
29 November 2000
Corporation Bank
0
30 March 2000
Syndicate Bank
0
09 March 2000
Oriental Bank Of Commerce
0
07 March 2000
Icici Limited
0
21 June 1999
Icici Limited
0
19 November 1998
Bank Of Baroda
0
17 October 2012
Bank Of Baroda
0
09 April 2012
Export-import Bank Of India
0
20 December 2011
Bank Of Baroda
0
21 December 2010
Bank Of Baroda
0
11 October 2005
Exprot-import Bank Of India
0
11 December 2009
Central Bank Of India
0
23 July 2008
Allahabad Bank
0
25 June 2021
Axis Bank Limited
0
29 July 2006
Syndicate Bank
0
11 July 2006
Syndicate Bank
0
23 June 2006
Syndicate Bank
0
23 June 2006
Syndicate Bank
0
20 March 2006
Bank Of Baroda
0
06 May 2016
Others
0
28 April 2010
Export Import Bank Of India
0
23 June 2006
Syndicate Bank
0
27 December 2019
Others
0
27 September 2007
The Karnataka Bank Limited
0
28 December 2007
Canara Bank
0
31 January 2008
Hdfc Bank Limited
0
27 March 2009
Dena Bank
0
08 April 2009
Department Of Biotechnology
0
26 May 2010
Central Bank Of India
0
18 April 2011
Indian Overseas Bank
0
25 March 2014
Export-import Bank Of India
0
28 March 2003
Allahbad Bank
0
13 September 2005
Bank Of Baroda
0
15 September 1997
Bank Of Baroda
0
18 November 1998
Others
0
11 September 1999
Idbi Bank Limited
0
07 January 2000
Industrial Developoment Bank Of India
0
29 September 2000
Bank Of Baroda
0
30 November 2000
Oriental Bank Of Commerc
0
08 March 2001
Exprot- Import Bank Of India
0
27 March 2001
Export - Import Bank Of India
0
29 March 2001
Union Bank Of India
0
16 May 2001
Union Bank Of India
0
28 May 2001
Corporation Bank
0
28 November 2001
Andhra Bank
0
21 January 2002
Union Bank Of India
0
12 April 2002
Canara Bank
0
23 October 2002
Bank Of Baroda
0
28 March 2003
Bank Of Baroda
0
29 March 2003
Canara Bank
0
06 October 2003
Canara Bank
0
26 March 2004
State Bank Of India
0
13 September 2005
Others
0
15 October 1999
Central Bank Of India
0
02 November 2000
Indian Overseas Bank
0
Documents
Form DPT-3-18012021-signed
Form MSME FORM I-21122020_signed
Copy of MGT-8-21122020
List of share holders, debenture holders;-21122020
Form MGT-7-21122020_signed
Form MGT-14-07122020_signed
Copy(s) of resolution(s) along with copy of explanatory statement under section 173-04122020
Optional Attachment-(1)-04122020
Form CHG-4-30112020_signed
Letter of the charge holder stating that the amount has been satisfied-27112020
Form CHG-1-11112020_signed
CERTIFICATE OF REGISTRATION FOR MODIFICATION OF CHARGE-20201111
Optional Attachment-(1)-09112020
Optional Attachment-(2)-09112020
Optional Attachment-(4)-09112020
Instrument(s) of creation or modification of charge;-09112020
Optional Attachment-(3)-09112020
Particulars of all joint charge holders;-09112020
Form PAS-6-14102020_signed
Form PAS-6-13102020_signed
Form CHG-4-05102020_signed
Declaration of the appointee director, Managing director, in Form No. DIR-2;-05102020
Form DIR-12-05102020_signed
Optional Attachment-(3)-05102020
Interest in other entities;-05102020
Optional Attachment-(2)-05102020
Optional Attachment-(1)-05102020
CERTIFICATE OF SATISFACTION OF CHARGE-20201005
Form DIR-12-03102020_signed
Evidence of cessation;-02102020
